BilezikianJ.P., PottsJ.T., FuleihanG.. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century.J Clin Endocrinol Metab2002; 87: 5353–61.
2.
NemethE.F., SteffeyM.E., HammerlandL.G.. Calcicimetics with potent and selective activity on the parathyroid calcium receptor.Proc Natl Acad Sci USA1998; 95: 4040–5.
3.
KawataT., ImanishiY., KobayashiK.. Direct in vitro evidence of the suppressive effect of cinacalcet HCL on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels.J Bone Miner Metab2006; 24: 300–06.
4.
BlockG.A., MartinK.J., de FranciscoA.L., TurnerS.A., AvramM.M., SuranyiM.G.. N Engl J Med2004; 350(15): 1516–25.
5.
LindbergJ.S., CulletonB., WongG., BorahM.F., ClarkR.V., ShapiroW.B.. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.J Am Soc Nephrol2005; 16(3): 800–7.
6.
Sajid-CrockettS., SingerF.R., HershmanJ.M.Cinacalcet for the treatment of primary hyperparathyroidism.Metabolism2008; 57(4): 517–21.
7.
IglesiasP., AisG., GonzálezA., TajadaP., García ArévaloC., Fernández PardoE., DíezJ.J.Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy.Am J Med Sci2008; 335(2La nefrolitiasi nel terzo millennio: una patologia di pe): 111–4.
8.
VestergaardP.Current pharmacological option for the management of primary hyperparathyroidism.Drugs2006; 66: 2189–211.
9.
SelbyP.L., PeacockM.Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal womem.N Engl J Med1996; 314: 1481–5.
10.
ChowC.C., ChanW.B., LiJ.K.. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism.J Clin Endocrinol Metab2003; 88: 581–7.
11.
Orr-WalkerB.J., EvansM.C., ClearwaterJ.M., HorneA., GreyA.B., ReidI.R.Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women.Arch Intern Med2000; 160(14): 2161–6.
